Drug Database · Clinicians

Ipratropium + Salbutamol

Also known as: albuterol (US name, for salbutamol)

Brands (76) Ambivent, Combipul, Pulmodual MDI…Show all

US brand (reference label): Combivent Respimat; not a Philippine-registered brand.

Adrenergic in combination with anticholinergic including combination with corticosteroid; Bronchodilator; and others PH FDA category
Fixed-dose combination.

Rx · Prescription drugOTC · Over-the-counter105 PH productsPNF-listedPhilHealth GAMOT
Dispensing: Over-the-counter (OTC) · Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 9832312e-0310-4ab6-8501-afa976fc7eb2, version date December 1, 2025 (Combivent Respimat · Boehringer Ingelheim Pharmaceuticals, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • COMBIVENT RESPIMAT is a combination of ipratropium bromide (an anticholinergic agent) and albuterol sulfate (a beta 2 -adrenergic agonist) indicated for use in patients with chronic obstructive pulmonary disease (COPD)…
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE COMBIVENT RESPIMAT is a combination of ipratropium bromide (an anticholinergic agent) and albuterol sulfate (a beta 2 -adrenergic agonist) indicated for use in patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator. COMBIVENT RESPIMAT Inhalation Spray is a combination of ipratropium bromide (an anticholinergic agent) and albuterol sulfate (a beta 2 ‑adrenergic agonist) indicated for: Patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator (1)

Contraindications

4 CONTRAINDICATIONS COMBIVENT RESPIMAT is contraindicated in the following conditions [see Warnings and Precautions (5.6)]: Hypersensitivity to any of the ingredients in COMBIVENT RESPIMAT Hypersensitivity to atropine or any of its derivatives Hypersensitivity to any of the ingredients in COMBIVENT RESPIMAT (4) Hypersensitivity to atropine or any of its derivatives (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

2 DOSAGE AND ADMINISTRATION The recommended dosage of COMBIVENT RESPIMAT is one inhalation four times a day. Patients may take additional inhalations as required; however, the total number of inhalations should not exceed six in 24 hours. Prior to first use, the COMBIVENT RESPIMAT cartridge is inserted into the COMBIVENT RESPIMAT inhaler and the unit is primed.

When using the unit for the first time, patients are to actuate the inhaler toward the ground until an aerosol cloud is visible and then repeat the process three more times. The unit is then considered primed and ready for use. If not used for more than 3 days, patients are to actuate the inhaler once to prepare the inhaler for use.

If not used for more than 21 days, patients are to actuate the inhaler until an aerosol cloud is visible and then repeat the process three more times to prepare the inhaler for use [see Patient Counseling Information (17)]. Safety and efficacy of additional doses of COMBIVENT RESPIMAT beyond six inhalations/24 hours have not been studied.

Also, safety and efficacy of extra doses of ipratropium or albuterol in addition to the recommended doses of COMBIVENT RESPIMAT have not been studied. For oral inhalation only One inhalation four times a day, not to exceed six inhalations in 24 hours (2)

Dosing: Altered kidney function

From the US FDA label · Renal impairment (pharmacokinetics)

Renal Impairment The pharmacokinetics of COMBIVENT RESPIMAT or ipratropium bromide has not been studied in patients with hepatic or renal insufficiency.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Safety and effectiveness of COMBIVENT RESPIMAT in pediatric patients have not been established. COMBIVENT RESPIMAT is indicated for use in patients with COPD on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator. This disease does not normally occur in children.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use In the 12-week trial in COPD, 48% of COMBIVENT RESPIMAT clinical trial patients were 65 years of age or over. In general, there were no marked differences between the proportion of patients with adverse reactions for the COMBIVENT RESPIMAT and CFC-propelled COMBIVENT Inhalation Aerosol treated patients.

Cardiac and lower respiratory disorders occurred less frequently in the patients under the age of 65 and were balanced across treatment groups. No overall differences in effectiveness were observed among treatment groups. Based on available data, no adjustment of COMBIVENT RESPIMAT dosage in geriatric patients is warranted.

Dosage forms

Philippines

  • Solution for inhalation: 2.5 mg + 500 mcg, 2.5 mg/500 mcg, 2.5 mg/500 mcg per 2.5 mL, 500 mcg/2.5 mg, 500 mcg/2.5 mg per 2.5 mL, 500 mcg/2.5 mg/2.5 mL
  • Solution for nebulization: 2.5 mg/500 mcg per 2.5 mL, 500 mcg/2.5 mg, 500 mcg/2.5 mg per 2.5 mL
  • Per ml solution for inhalation: 1 mg/200 mcg, 200 mcg/1 mg
  • Per actuation metered dose inhaler: 20 mcg/100 mcg, 100 mcg/20 mcg
  • ) solution for inhalation: 1 mg/200 mcg per mL (2.5 mg/500 mcg per 2.5 mL, 200 mcg/1 mg per mL (500 mcg/2.5 mg per 2.5 mL
  • Nebulizer solution: 2.5 mg/500 mcg per 2.5 mL
  • Metered dose inhaler: 100 mcg/20 mcg
  • Per actuation suspension metered dose inhaler: 20 mcg/100 mcg
  • Solution for inhalation solution for inhalation: 500 mcg/2.5 mg per 2.5 mL

Registered products in the Philippines

105 products registered with the Food and Drug Administration (FDA) Philippines list Ipratropium + Salbutamol as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Salbutamol (as Sulfate) + lpratropium Bromide (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products105
Philippine FDA-registered products for Ipratropium + Salbutamol
Package insert
AerosyncSalbutamol (as sulfate) + Ipratropium Bromide
2.5 mg / 500 mcg per 2.5 mL Solution for InhalationLDPE ampoule x 5 mL (2.5 mL net content) by strips of 7’s (Box of 35’s)
Rx
Ahlcon Parenterals (India) LimitedIndia
Premier Pharmaceuticals Marketing Corp.Importer: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma
DRP-13901-02
May 15, 2028
AerosyncSalbutamol (as sulfate) + Ipratropium Bromide
2.5 mg/500 mcg per 2.5 mL Solution for Inhalation2.5 mL (Net Content) in 5 mL LDPE Vial in Aluminum Foil Strip x 7’s (Box of 35’s)
Rx
Ahlcon Parenterals (India) LimitedIndia
Premier Pharmaceuticals Marketing Corp.Importer: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma
DRP-13048-11
Nov 24, 2027
AetropsalSalbutamol (as sulfate) + Ipratropium bromide
2.5 mg/ 500 mcg per 2.5 mL Solution for Inhalation2.5mL (Net Content) in 5 mL LDPE Vial in Aluminum Foil Strip x 7's (Box of 35's)
Rx
AHLCON PARENTERALS (INDIA) LIMITEDIndia
DYNASTY PHARMACEUTICALSImporter: AMBICARE PHARMACEUTICALS INC.Trader: HIGHKON PHARMA
DRP-13048-03
Nov 24, 2027
AetropsalIpratropium Bromide + Salbutamol (as Sulfate)
200 mcg/1 mg per mL Solution for Inhalation2.5mL Translucent LDPE Ampoule (5 Ampoules Enclosed in Aluminum Foil Pouch) (Box of 5's and 20's)
Rx
Geofman PharmaceuticalsPakistan
Dynasty PharmaceuticalsImporter: Sahar International Trading, Inc.
DRP-5276-04
Jul 24, 2027
Airzol PlusIpratropium bromide + Salbutamol (as sulfate)
500 mcg/2.5 mg per 2.5 mL Solution for InhalationLDPE plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 5 ampoules, Box of 25’s) and (Box of 6 ampoule strips x 5 ampoules, Box of 30's) Not Applicable
Rx
Legency Remedies Pvt. Ltd.India
Roymed PharmaceuticalImporter: Suhitas Pharmaceuticals Inc.
DRP-13475-11
Feb 27, 2028
Alventil PlusSalbutamol (as sulfate) + Ipratropium bromide
1 mg/200 mcg per mL (2.5 mg/500 mcg per 2.5 mL) Solution for InhalationLDPE plastic ampoule x 2.5 mL (net content) in aluminum pouch x 5's (Box of 30's)
Rx
Legency Remedies Pvt. Ltd.India
Endure Medical, Inc.
DRP-16038
Oct 18, 2029
AlveoventSalbutamol (as sulfate) + Ipratropium Bromide
2.5 mg/500 mcg per 2.5 mL Solution for InhalationLDPE ampoule x 5 mL (2.5 mL net content) by strips of 7’s (Box of 35’s)
Rx
Ahlcon Parenterals (India) LimitedIndia
228 Pharma TradingImporter: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma
DRP-13901-01
May 15, 2028
AmbiventSalbutamol (as sulfate) + Ipratropium (as bromide)
2.5 mg /500 mcg per 2.5 mL Solution for InhalationLDPE Nebule x 2.5 mL (Box of 35's)
Rx
Ahlcon Parenterals (India) LimitedIndia
Madecs Pharma CorporationImporter: I.E. Medica, Inc.
DRP-1419-10
May 19, 2027
AMBIVENTSalbutamol (as sulfate ) + Ipratropium bromide
2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL net content in 5 mL LDPE nebule (Box of 30 nebules in strips of 5's)
Rx
Amanta Healthcare LimitedIndia
MADECS PHARMA CORPORATIONImporter: I.E. Medica, Inc.Trader: MGRM Medicare Private Limited
DRP-4672-02
Feb 2, 2028
AmbiventSalbutamol (as Sulfate) + Ipratropium Bromide
2.5mg / 500mcg per 2.5ml Solution for Nebulization2.5ml LDPE Form-Fill Seal ampoule in Aluminum pouch (Box of 25's)
Rx
Legency Remedies Pvt. Ltd.India
Madecs Pharma CorporationImporter: Hillcross Prime Inc.
DRP-11062-06
Jan 21, 2027
AmsulduoSalbutamol (as sulafte) + Ipratropium Bromide
2.5 mg/500 mcg per 2.5 mL Solution For Inhalation5 mL LDPE vial x 2.5 mL wrapped in aluminium foil in strips x 7's
Rx
Ahlcon Parenterals (India) LimitedIndia
Ambicare PharmaceuticalsImporter: Ambicare Pharmaceuticals, Inc.Trader: Highkon Pharma
DRP-13901
May 15, 2028
Asmagone PlusSalbutamol (as sulfate) + Ipratropium (as bromide)
2.5 mg / 500 mcg per 2.5 mL Solution for InhalationLDPE Nebule x 2.5 mL (Box of 35's)
Rx
Ahlcon Parenterals (India) LimitedIndia
TGP Pharma Inc.Importer: I.E. Medica, Inc.
DRP-1419-09
May 19, 2027
Asmagone PlusSalbutamol (as Sulfate)+ Ipratropium Bromide
2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL net content in 5 mL LDPE nebule (Box of 30 nebules in strips of 5's)
Rx
Amanta Healthcare LimitedIndia
TGP Pharma Inc.Importer: I.E. Medica Inc.Trader: MGRM Medicare Limited
DRP-4672-01
Oct 29, 2028
Aura 2Salbutamol (as Sulfate) + Ipratropium Bromide
2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL LDPE Form-Fill-Seal Ampoule in aluminum pouch (Box of 25's)
Rx
Legency Remedies Pvt. Ltd.India
All-Bio Pharma, Inc.Importer: Hillcross Prime, Inc.
DRP-11062-08
Jan 21, 2027
Aura PlusSalbutamol (as sulfate) + Ipratropium (as bromide)
2.5 mg/500 mcg per 2.5 mL Solution for InhalationLDPE Nebule x 2.5 mL (Box of 35's)
Rx
Ahlcon Parenterals (India) LimitedIndia
All-Bio Pharma, Inc.Importer: I.E. Medica, Inc.
DRP-1419-11
May 19, 2027
Aura PlusSalbutamol (as sulfate) + Ipratropium Bromide
2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL net content in 5 mL LDPE nebule (Box of 30 nebules in strips of 5's)
Rx
Amanta Healthcare LimitedIndia
All-Bio Pharma, Inc.Importer: I.E. Medica, Inc.Trader: MGRM Medicare Private Limited
DRP-4672-03
Oct 29, 2028
Bio-AireSalbutamol (as sulfate) + Ipratropium Bromide
1 mg / 200 mcg per mL Solution for Inhalation2.5 mL polypropylene ampoule with protective cap (Box of 30's)
Rx
Ha Noi CPC1 Pharmaceutical Joint Stock CompanyVietnam
Bio Erixx Pharma DistributionImporter: AMB HK Enterprises Inc.
DRP-12785-03
Oct 7, 2027
BioventIpratropium Bromide + Salbutamol (as Sulfate)
200 mcg/1 mg per mL Solution for Inhalation2.5mL Transluscent LDPE Ampoule (Box of 5's)
Rx
Geofman PharmaceuticalsPakistan
Amson PharmaceuticalsImporter: Sahar International Trading, Inc.
DRP-5276-01
Jul 24, 2027
BrevonebSalbutamol (as Sulfate) + Ipratropium Bromide
2.5 mg / 500 mcg per 2.5 mL Solution For Inhalation2.5 mL (Net Content) in 5 mL LDPE Vial in Aluminum Foil Strip x 7's (Box of 35's)
Rx
Ahlcon Parenterals (India) LimitedIndia
Ambicare Pharmaceuticals, Inc.
DRP-13048
Nov 24, 2027
Brodix PlusSalbutamol (as sulfate) + Ipratropium (as bromide)
2.5 mg/500 mcg per 2.5 mL Solution for InhalationLDPE Nebule x 2.5 mL (Box of 35's)
Rx
Ahlcon Parenterals (India) LimitedIndia
Medethix, Inc.Importer: I.E. Medica Inc.
DRP-1419-04
May 19, 2027
Brodix PlusSalbutamol (as Sulfate) + lpratropium BromideVariant spelling
2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL net content in 5 mL LDPE nebule Box of 30 nebules in strips of 5's
Rx
Amanta Healthcare Ltd.India
MedEthix Inc.Importer: I.E. Medica Inc.Trader: MGRM Medicare Pri vate Limited
DRP-4672-04
Oct 29, 2028
BronchomideSalbutamol (as sulfate) + Ipratropium bromide
1 mg/200 mcg per mL Solution for InhalationPolypropylene ampoule x 2.5 mL with protective cap (Box of 10’s, 25’s and 30’s)
Rx
Hebei Tiancheng Pharmaceutical Co., Ltd.China
Philrx Pharma Inc.
DRP-16273
Jan 20, 2030
BronchosalSalbutamol (As Salbutamol Sulfate) + Ipratropium Bromide
1 mg/200 mcg per mL Solution for Inhalation2.5 mL polypropylene ampoule with protective cap (Box of 10's)
Rx
Ha Noi CPC1 Pharmaceutical Joint Stock CompanyVietnam
AMB HK Enterprises IncImporter: AMB HK Enterprises Inc.
DRP-12785
Oct 7, 2027
BronchoservSalbutamol (as Sulfate) + Ipratropium Bromide
2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL LDPE Form-Fill Seal Ampoule in Aluminum Pouch (Box of 25’s)
Rx
Legency Remedies Pvt. Ltd.India
Truserve Pharmaceutical DistributorImporter: Hillcross Prime Inc.
DRP-11062-03
Jan 21, 2027
Broncovent PlusIpratropium (as bromide) + Salbutamol (as sulfate)
200 mcg / 1 mg per mL (500 mcg / 2.5 mg per 2.5 mL) Solution for Inhalation2.5 mL Polypropylene Ampoule x 5's in aluminum pouch (Box of 30's) and 7's in aluminum pouch (Box of 35's)
Rx
Althea Pharma Pvt. LtdIndia
Kaufmann Pharma Inc.Importer: Ollen Pharma Trading Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-10970-01
Dec 29, 2026
Broncovent PlusIpratropium bromide + Salbutamol (as sulfate)
500 mcg/ 2.5 mg Solution for InhalationLDPE plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 5 ampoules)
Rx
Legency Remedies Pvt. Ltd.India
Kaufmann Pharma Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-13475-03
Feb 27, 2028
Co-VentreeSalbutamol (as sulfate) + Ipratropium Bromide
1 mg/200 mcg per mL Solution for Inhalation2.5 mL polypropylene ampoule with protective cap (Box of 10's)
Rx
Ha Noi CPC1 Pharmaceutical Joint Stock CompanyVietnam
PharmaTree Inc.Importer: AMB HK Enterprises Inc
DRP-12785-02
Oct 7, 2027
CombimistIpratropium Bromide + Salbutamol (as sulfate)
500 mcg/2.5 mg Solution for InhalationLDPE plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 5 ampoules)
Rx
Legency Remedies Pvt. Ltd.India
Zydus Healthcare Philippines Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-13475-01
Feb 27, 2028
CombipulSalbutamol (as sulfate) + Ipratropium (as bromide)
1mg/200mcg per mL (2.5mg/500mcg per 2.5mL) Solution for InhalationLDPE plastic ampoule x 2.5mL (net content) in aluminum pouch x 5's (Box of 30's)
Rx
Legency Remedies Pvt. Ltd.India
Phil Pharmawealth, Inc.Importer: Endure Medical, Inc.
DRP-16038-01
Oct 18, 2029
CombipulIpratropium Bromide + Salbutamol (as Sulfate)
20 mcg/100 mcg per Actuation Metered Dose Inhaler (CFC-Free)FCP Plasma Coated Aluminum Aerosol canister containing 200 metered doses + Polypropylene actuator (Box of 1's) Box of 1's
Rx
Cipla Ltd. (Unit I)India
Phil Pharmawealth, Inc.
DR-XY41122
Oct 15, 2028
CombipulIpratropium Bromide + Salbutamol (as Sulfate)
500 mcg / 2.5 mg Solution for NebulizationLDPE nebule x 2.5 mL Box of 20's in Strips of 5 enclosed in an Aluminum Pouch
Rx
Cipla Ltd.India
Phil Pharmawealth, Inc.
DRP-6160
Sep 8, 2030
Combivent UDVIpratropium Bromide + Salbutamol (as Sulfate)
500 mcg/ 2.5 mg/ 2.5 mL Solution for InhalationLDPE Vial x 2.5 mL (Box of 20's)
Rx
Laboratoire UnitherFrance
Importer: Boehringer Ingelheim (Philippines), Inc.
DRP-7891
Feb 11, 2031
DuaventIpratropium bromide (as monohydrate) + Salbutamol (as sulfate)
500 mcg / 2.5 mg per 2.5 mL Solution for Nebulization2.5 mL LDPE blow-fill-seal ampoule x 5' in an aluminum/PE/PET laminated pouch (Box of 20's)
Rx
Amherst Parenterals, Inc.Philippines
Trader: UNILAB, Inc.
DRP-16154
Dec 22, 2026
DuaventIpratropium bromide (as monohydrate) + Salbutamol (as sulfate)
500 mcg/2.5 mg per 2.5 mL Solution For Nebulization2.5 mL LDPE blow-fill-seal ampoule x 5's in an aluminum/PE/PET laminated pouch (Box of 20's)
Rx
Amherst Parenterals, Inc.Philippines
Trader: UNILAB, Inc.
DR-XY47628
Dec 22, 2026
DuodairSalbutamol (as sulfate) + Ipratropium (as bromide)
2.5 mg/500 mcg per 2.5 mL Solution for Inhalation5 mL LDPE Vial in Aluminum Foil Pouch x 7's (Box of 7's and Box of 35’s)
Rx
Ahlcon Parenterals (India) LimitedIndia
GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc.
DRP-11882-02
May 16, 2027
DuolinSalbutamol (as sulfate) + Ipratropium Bromide
100 mcg/20 mcg per Actuation Metered Dose Inhaler (CFC Free) (200 doses)Aluminum aerosol container containing 200 metered doses + polypropylene actuator (in a box)
Rx
Cipla Ltd. (Unit II)India
Healol Pharma Corporation
DR-XY46129
Oct 25, 2027
DuomedSalbutamol (as Sulfate) + Ipratropium Bromide
2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL LDPE Form-Fill Seal Ampoule in aluminum pouch (Box of 25’s)
Rx
Legency Remedies Pvt. Ltd.India
Medwise, Inc.Importer: Hillcross Prime Inc.
DRP-11062-02
Jan 21, 2027
Duorite RespulesSalbutamol (as Sulfate) + Ipratropium Bromide
2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL LDPE Form-Fill-Seal Ampoule in aluminum pouch (Box of 25's)
Rx
Legency Remedies Pvt. Ltd.India
Hillcross Prime Inc.
DRP-11062
Jan 21, 2027
DuosalbiumSalbutamol (as sulfate) + Ipratropium bromide
2.5 mg / 500 mcg per 2.5 mL Solution for Inhalation2.5 mL (Net Content) in 5 mL LDPE Vial in Aluminum Foil Strip x 7's (Box of 35's)
Rx
Ahlcon Parenterals (India) LimitedIndia
Ambica International CorporationImporter: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma
DRP-13048-04
Nov 24, 2027
DuosanSalbutamol (as Sulfate) + Ipratropium Bromide
2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL LDPE Form-Fill Seal Ampoule in aluminum pouch (Box of 25’s)
Rx
Legency Remedies Pvt. Ltd.India
Sanimed Pharmaceuticals Inc.Importer: Hillcross Prime Inc.
DRP-11062-01
Jan 21, 2027
DuoshangSalbutamol (as Sulfate) + Ipratropium Bromide
2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL LDPE Form-Fill Seal Ampoule in aluminum pouch (Box of 25's)
Rx
Legency Remedies Pvt. Ltd.India
Grabernoll Pharmaceutical CorporationImporter: Hillcross Prime, Inc.
DRP-11062-09
Jan 21, 2027
EmbuventSalbutamol (as sulfate) + Ipratropium (as bromide)
2.5 mg/500 mcg per 2.5 mL Solution for InhalationLDPE Nebule x 2.5 mL (Box of 35's)
Rx
Ahlcon Parenterals (India) LimitedIndia
Emhealthcare Pharma Traders Inc.Importer: I.E. Medica, Inc.
DRP-1419-14
May 19, 2027
Eurosalbu PlusIpratropium Bromide + Salbutamol (as sulfate)
500 mcg / 2.5 mg Solution for InhalationLDPE Plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 5 ampoules)
Rx
Legency Remedies Pvt. Ltd.India
Euro-Care Products PhilippinesImporter: Suhitas Pharmaceuticals Inc.
DRP-13475-02
Feb 27, 2028
GopraSalbutamol (as sulfate) + Ipratropium (as bromide)
2.5 mg/500 mcg per 2.5 mL Solution for Inhalation5 mL LDPE Vial in Aluminum Foil Pouch x 7's (Box of 7's and Box of 35's)
Rx
Ahlcon Parenterals (India) LimitedIndia
Applied Pharmaceutical Distribution Inc.Importer: Medinova Pharmaceutical Inc.
DRP-11882-03
May 16, 2027
Govent PlusIpratropium bromide + Salbutamol (as sulfate)
500 mcg/2.5 mg per 2.5 mL Solution for InhalationLDPE plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 6 ampoules, Box of 30's)
Rx
Legency Remedies Pvt. LtdIndia
Applied Pharmaceutical Distribution IncImporter: Suhitas Pharmaceuticals Inc.
DRP-13475-09
Feb 27, 2028
Hivent PlusIpratropium Bromide + Salbutamol
500 mcg/2.5 mg per 2.5 mL Solution for Inhalation2.5 mL LDPE Ampoule x 5 Ampoules per Foil Pouch (Box of 6 Foil Pouches)
Rx
Euro-Med Laboratories Phil., Inc.Philippines
—
DR-XY46417
Sep 14, 2028
I-Breath PlusSalbutamol (As Sulfate) + Ipratropium Bromide
100mcg/20mcg Metered Dose InhalerAluminum canister fitted with metering valve x 200 metered doses (Box of 1's)
Rx
The ACME Laboratories Ltd.Bangladesh
Bell-Kenz Pharma, Inc.Importer: Euro Generics International Phils., Inc.
DR-XY45413
Feb 28, 2028
INHALIN IPRASalbutamol (as sulfate) + Ipratropium bromide
2.5 mg/500 mcg per 2.5 mL Nebulizer SolutionLDPE Nebule x 2.5 mL (Box of 20's)
Rx
Eurolife Healthcare Pvt. Ltd.India
Aglobal Care, Inc.
DRP-17000
Sep 4, 2030
ipracareIpratropium Bromide + Salbutamol (as Sulfate)
200 mcg/1mg per mL Solution for Inhalation2.5mL Translucent LDPE Ampoule (Box of 5's, 20's and 30's)
Rx
Geofman PharmaceuticalsPakistan
North Care Pharmaceutical DistributorshipImporter: Sahar International Trading, Inc.
DRP-5276-02
Jul 24, 2027
IpradenIpratropium Bromide + Salbutamol (as Sulfate)
200 mcg/1 mg per mL Solution for Inhalation2.5mL Translucent LDPE Ampoule (5 Ampoule Enclosed in Aluminum Foil Pouch) (Box of 5's)
Rx
Geofman PharmaceuticalsPakistan
Cyden Medicale TradingImporter: Sahar International Trading, Inc.
DRP-5276-05
Jul 24, 2027
IpraferIpratropium Bromide + Salbutamol (as Sulfate)
200 mcg/1 mg per mL Solution for inhalation2.5 mL Translucent LDPE Ampoule (5 Ampoules Enclosed in Aluminum Foil Pouch) (Box of 5's and 30's)
Rx
Geofman PharmaceuticalsPakistan
Ferma Drug EnterprisesImporter: Sahar International Trading Inc.
DRP-5276-06
Jul 24, 2027
IpralinIpratropium bromide + Salbutamol (as sulfate)
20 mcg/100 mcg per actuation Suspension Metered Dose InhalerAluminum canister with metered valve and actuator x 200 actuations (Box of 1's)
Rx
Aristopharma Ltd.Bangladesh
Sahar International Trading Inc.
DR-XY45781
Feb 14, 2027
IpralinIpratropium bromide + Salbutamol (as sulfate)
20 mcg/100 mcg per actuation Suspension Metered Dose InhalerAluminum canister with metered valve and actuator x 200 actuations (Box of 1's)
Rx
Aristopharma Ltd.Bangladesh
Sahar International Trading Inc.
DRP-12203
Feb 14, 2027
IpranebIpratropium Bromide + Salbutamol (as Sulfate)
200 mcg/1mg per mL Solution for Inhalation2.5 mL Translucent LDPE Ampoule (Box of 5's)
Rx
Geofman PharmaceuticalsPakistan
Skymed Pharma DistributorImporter: Sahar International Trading Inc.
DRP-5276-03
Jul 24, 2027
IprasalSalbutamol (as sulfate) + Ipratropium bromide
100 mcg/20 mcg Metered Dose Inhaler1 Aluminum Canister x 200 doses per box Not Applicable
Rx
Yangzhou No. 3 Pharmaceutical Co., LtdChina
Endure Medical Inc.
DR-XY44139
Feb 9, 2031
IprasalcareIpratropium Bromide + Salbutamol (As Sulfate)
500 mcg/2.5 mg per 2.5 mL Solution for Inhalation Solution For Inhalation2.5 mL LDPE nebules x 10’s in aluminum pouch (Box of 10’s)
Rx
Joincare Haibin Pharmaceutical Co., Ltd.China
Joincare Pharma Philippines, Inc.Trader: N/A
DRP-14774
Jun 15, 2031
IpraventIpratropium Bromide + Salbutamol (as Sulfate)
200 mcg/1 mg per mL Solution for Inhalation2.5mL Translucent LDPE Ampoule (5 Ampoules Enclosed in Aluminum Foil Pouch) (Box of 5's and 30's)
Rx
GEOFMAN PHARMACEUTICALSPakistan
SAHAR INTERNATIONAL TRADING INC.
DRP-5276
Jul 24, 2027
Iprax-MolSalbutamol(as sulfate) + Ipratropium Bromide
2.5 mg + 500 mcg SOLUTION FOR INHALATION5 LDPE Respules x 2.5 mL packed in aluminium foil pouch (Box of 20's)
Rx
Axa Parenterals LimitedIndia
S.M.H.P. Marketing & Consultancy
DR-XY47648
Jan 7, 2027
Ipsa-DuoSalbutamol (as sulfate) + Ipratropium bromide
2.5 mg/500 mcg per 2.5 mL Solution for Inhalation2.5mL (Net Content) in 5 mL LDPE Vial in Aluminum Foil Strip x 7's (Box of 35's)
Rx
Ahlcon Parenterals (India) LimitedIndia
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma
DRP-13048-05
Nov 24, 2027
LomatubsalSalbutamol (as sulfate) + Ipratropium bromide
2.5 mg/ 500 mcg per 2.5 mL Solution for Inhalation2.5 mL (Net Content) in 5 mL LDPE Vial in Aluminum Foil Strip x 7's (Box of 35's)
Rx
Ahlcon Parenterals (India) LimitedIndia
Diafarm, Inc.Importer: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma
DRP-13048-06
Nov 24, 2027
LupiventSalbutamol (as Sulfate) + Ipratropium Bromide
2.5mg/500mcg per 2.5mL Solution for Inhalation2.5mL LDPE Polyampoule x 7's Box of 21's and 35's
Rx
Ahlcon Parenterals (India) LimitedIndia
Importer: Lupin Philippines IncTrader: LUPIN LIMITED
DRP-4504
Sep 4, 2027
MultiventSalbutamol (as Sulfate) + Ipratropium Bromide
2.5 mg/500 mcg per 2.5 mL Solution for Inhalation2.5 mL LDPE Polyampoule x 7's (Box of 35's)
Rx
Ahlcon Parenterals (India) LimitedIndia
Multicare Pharmaceuticals Phils. Inc.Importer: Lupin Philippines, Inc.Trader: Lupin Limited
DRP-4504-01
Sep 4, 2027
Multivent MDISalbutamol (as sulfate) + Ipratropium Bromide
100 mcg / 20 mcg per Actuation Metered Dose InhalerAluminum Canister with pump actuator x 12g (Box of 1's)
Rx
Midas-Care Pharmaceuticals Pvt. Ltd.India
Multicare Pharmaceuticals Phils. Inc.Importer: MedEthix, Inc.
DRP-4809-04
Jun 28, 2027
NebsadualSalbutamol (as sulfate) + Ipratropium bromide
2.5 mg/500 mcg per 2.5 mL Solution for Inhalation2.5mL (Net Content) in 5 mL LDPE Vial in Aluminum Foil Strip x 7's (Box of 35's)
Rx
Ahlcon Parenterals (India) LimitedIndia
Diafarm, Inc.Importer: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma
DRP-13048-07
Nov 24, 2027
NebulentIpratropium bromide + Salbutamol (as sulfate)
500 mcg/2.5 mg per 2.5 mL Solution for InhalationLDPE plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 5 ampoules)
Rx
Legency Remedies Pvt. Ltd.India
Neo-Care PhilippinesImporter: Suhitas Pharmaceuticals Inc.
DRP-13475-05
Feb 27, 2028
NoneSalbutamol (as sulfate) + Ipratropium (as bromide)
2.5 mg / 500 mcg per 2.5 mL Solution for Inhalation5 mL LDPE Vial in Aluminum Foil Pouch x 7's (Box of 35's)
Rx
Ahlcon Parenterals (India) LimitedIndia
Qualifirst Health Inc.Importer: Medinova Pharmaceutical Inc.
DRP-11882-04
May 16, 2027
noneSalbutamol (as sulfate) + Ipratropium bromide.
2.5 mg/ 500 mcg per 2.5 mL Solution for NebulizationLDPE nebule x 5's in aluminum pouch (Box of 20's)
Rx
Cipla Limited (Unit I)India
SMHP Pharmaceuticals Incorporated.
DRP-14860
Jan 25, 2029
NoneSalbutamol (as sulfate) + Ipratropium bromide
2.5 mg/500 mcg per 2.5 mL Solution for Inhalation2.5 mL (net content) in 5 mL LDPE vial in Aluminum Foil Strip x 7’s (Box of 35’s)
Rx
Ahlcon Parenterals (India) LimitedIndia
Ambica International CorporationImporter: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma
DRP-13048-01
Nov 24, 2027
NoneSalbutamol (as sulfate) + Ipratropium (as bromide)
2.5 mg/500 mcg per 2.5 mL Solution for InhalationLDPE Nebule x 2.5 mL Box of 35's
Rx
Ahlcon Parenterals (India) LimitedIndia
Madecs Pharma CorporationImporter: I.E. Medica, Inc.
DRP-1419-02
May 19, 2027
NoneSalbutamol (as sulfate) + Ipratropium (as bromide)
2.5 mg/500 mcg per 2.5 mL Solution for InhalationLDPE Nebule x 2.5 mL (Box of 35's)
Rx
Ahlcon Parenterals (India) LimitedIndia
Actimed, Inc.Importer: I.E. Medica, Inc.
DRP-1419-07
May 19, 2027
NoneSalbutamol (as sulfate) + Ipratropium (as bromide)
2.5 mg/500 mcg per 2.5 mL Solution for InhalationLDPE Nebule x 2.5 mL (Box of 35's)
Rx
Ahlcon Parenterals (India) LimitedIndia
Vivilon Pharmaceuticals Inc.Importer: I.E. Medica, Inc.
DRP-1419-12
May 19, 2027
NoneIpratropium (as bromide) + Salbutamol (as sulfate)
200 mcg/ 1 mg per mL (500mcg/2.5 mg per 2.5 mL) Solution for Inhalation2.5 mL Polypropylene Ampoule x 5's in aluminum pouch (Box of 30's) and x 7's in aluminum pouch (Box of 35's)
Rx
Althea Pharma Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Ollen Pharma Trading Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-10970-02
Dec 29, 2026
Oranair PlusIpratropium Bromide + Salbutamol (as Sulfate)
500 mcg/2.5 mg per 2.5 mL Solution for InhalationLDPE plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 5 ampoules)
Rx
Legency Remedies Pvt. Ltd.India
Orange Biotec Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-13475-04
Feb 27, 2028
Oustma PlusSalbutamol (as sulfate) + Ipratropium (as bromide)
2.5 mg/500 mcg per 2.5 mL Solution for InhalationLDPE Plastic nebule x 2.5 mL (Box of 35's)
Rx
Ahlcon Parenterals (India) LimitedIndia
Vivilon Pharmaceuticals Inc.Importer: I.E. Medica, Inc.
DRP-1419-05
May 19, 2027
PilltropiumSalbutamol (as sulfate) + Ipratropium bromide
2.5 mg/500 mcg per 2.5 mL Solution for Inhalation2.5 mL (Net Content) in 5 mL LDPE Vial in Aluminum Foil Strip x 7’s (Box of 35’s)
Rx
Ahlcon Parenterals (India) LimitedIndia
Ambitech Biopharmaceuticals Inc.Importer: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma
DRP-13048-08
Nov 24, 2027
PramolmaxSalbutamol (as Sulfate) + Ipratropium Bromide
2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL LDPE Form-Fill-Seal Ampoule in aluminum pouch (Box of 25's)
Rx
Legency Remedies Pvt. Ltd.India
Sefamax Pharmaceutical Products DistributionImporter: Hillcross Prime, Inc.
DRP-11062-05
Jan 21, 2027
PulmodualSalbutamol (as sulfate) + Ipratropium bromide
2.5 mg / 500 mcg Solution for Inhalation5 LDPE Respules x 2.5 mL Packed in Aluminum Foil Pouch (Box of 20's)
Rx
Axa Parenterals LimitedIndia
The Cathay Drug Co., Inc.Importer: Preventia Healthcare Inc.
DRP-12113-01
Jan 7, 2027
PulmodualIpratropium (as bromide) + Salbutamol (as sulfate)
500 mcg/2.5 mg per 2.5 mL Solution for Inhalation20 mL Ribbed Boston Round Amber Glass Bottle with Euro Dropper and Plastic Cap (Box of 1's)
Rx
EL Laboratories, Inc.Philippines
Trader: The Cathay Drug Co., Inc.
DR-XY35413
Feb 9, 2029
Pulmodual MDISalbutamol (as Sulfate) + Ipratropium Bromide
100 mcg / 20 mcg per Actuation Metered Dose InhalerAluminum Canister with pump actuator x 12 g (Box of 1's)
Rx
Midas-Care Pharmaceuticals, Pvt. Ltd.India
The Cathay Drug Co., Inc.Importer: Medethix, Inc.
DRP-4809-03
Jun 28, 2027
Pulmodual MDISalbutamol (as sulfate) + Ipratropium Bromide
100 mcg/20 mcg per Actuation Metered Dose InhalerAluminum Canister with Pump Actuator x 12 g (Box of 1's)
Rx
Midas-Care Pharmaceuticals Pvt. LtdIndia
The Cathay Drug Co., Inc.Importer: Medethix, Inc.
DRP-4809-02
Jun 28, 2027
Pulmodual MDISalbutamol (As Sulfate) + Ipratropium Bromide
100mcg/20mcg Per Actuation Metered Dose InhalerAluminum Canister with pump actuator x 12 g (Box of 1's)
Rx
Midas-Care Pharmaceuticals Pvt. Ltd.India
The Cathay Drug Co., Inc.Importer: MedEthix, Inc.
DRP-4809
Jun 28, 2027
RelaxsaphIpratropium (as Bromide) + Salbutamol (as Sulfate)
200 mcg/ 1 mg per mL (500 mcg/ 2.5 mg per 2.5 mL) Solution For Inhalation2.5 mL Polypropylene Ampoule x 5's in aluminum pouch (Box of 30's) and x 7's in aluminum pouch (Box of 35's)
OTC
Althea Pharma Pvt. Ltd.India
Ollen Pharma Trading Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-10970
Dec 29, 2026
Resease-IPSalbutamol (as sulfate) + Ipratropium bromide
2.5mg/500mcg solution for Inhalation5 LDPE Respules x 2.5 mL Packed in Aluminum Foil Pouch (Box of 20's)
Rx
Axa Parenterals Ltd.India
Slanchi Pharma Inc.Importer: Preventia Healthcare Inc.
DRP-12113-02
Jan 7, 2032
Resposal-ISalbutamol (as sulfate) + Ipratropium (as bromide)
2.5 mg / 500 mcg per 2.5 mL Solution for InhalationLDPE Nebule x 2.5 mL (Box of 35's)
Rx
Ahlcon Parenterals (India) LimitedIndia
Vivilon Pharmaceuticals Inc.Importer: I.E. Medica, Inc.
DRP-1419-13
May 19, 2027
Resposal-ISalbutamol (as sulfate) + Ipratropium Bromide
2.5 mg/500 mcg per 2.5 mL Solution for Nebulization2.5 mL net content in 5 mL LDPE nebule (Box of 30 nebules in strips of 5's)
Rx
Legency Remedies Pvt. Ltd.India
I.E. Medica Inc.
DRP-4672
Feb 2, 2028
Retavent PlusSalbutamol (as sulfate)+ Ipratropium (as bromide)
2.5 mg / 500 mcg per 2.5 mL Solution for Inhalation5 mL LDPE Vial in Aluminum Foil Pouch x 7’s (Box of 7’s and 35’s)
Rx
Ahlcon Parenterals (India) LimitedIndia
Reta DrugImporter: Medinova Pharmaceutical Inc.
DRP-11882-01
May 16, 2027
Retavent PlusSalbutamol (as sulfate) + Ipratropium bromide
2.5mg/500 mcg per 2.5mL Nebulizer SolutionLDPE Nebule x 2.5mL (Box of 20"s)
Rx
Eurolife Healthcare Pvt. Ltd..India
Reta DrugImporter: Aglobal Care, Inc.
DRP-17000-01
Sep 4, 2030
Retavent PlusIpratropium bromide + Salbutamol (as sulfate)
500 mcg / 2.5 mg Solution for InhalationLDPE plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 5 ampoules)
Rx
Legency Remedies Pvt. Ltd.India
Reta DrugImporter: Suhitas Pharmaceuticals Inc.
DRP-13475-06
Feb 27, 2028
Retavent Plus RSalbutamol (as sulfate) + Ipratropium bromide
2.5 mg / 500 mcg per 2.5 mL Solution for Inhalation2.5 mL (Net Content) in 5 mL LDPE Vial in Aluminum Foil Strip x 7's (Box of 35's)
Rx
Ahlcon Parenterals (India) LimitedIndia
Reta DrugImporter: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma
DRP-13048-09
Nov 24, 2027
SalbipraSalbutamol (as Sulfate) + Ipratropium Bromide
2.5 mg / 500 mcg per 2.5 mL Solution for Nebulization2.5 mL LDPE Form-Fill-Seal Ampoule in aluminum pouch (Box of 25's)
Rx
Legency Remedies Pvt. Ltd.India
Euroasia Pharmaceuticals, Inc.Importer: Hillcross Prime, Inc.
DRP-11062-07
Jan 21, 2027
SalbipraSalbutamol (as sulfate) + Ipratropium bromide
2.5mg/500mcg per 2.5mL Nebulizer SolutionLDPE Nebule x 2.5ml (Box of 20's)
Rx
Eurolife Healthcare Pvt. Ltd.India
Euroasia Pharmaceuticals, IncImporter: AGlobal Care, Inc.
DRP-17000-02
Sep 4, 2030
SalbproduoSalbutamol (as sulfate) + Ipratropium bromide
2.5 mg / 500 mcg per 2.5 mL Solution for Inhalation2.5 mL (Net Content) in 5mL LDPE Vial in Aluminum Foil Strip x 7's (Box of 35's)
Rx
Ahlcon Parenterals (India) LimitedIndia
Ambitech Biopharmaceuticals Inc.Importer: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma
DRP-13048-10
Nov 24, 2027
SalbubamIpratropium bromide + Salbutamol (as sulfate)
500 mcg/2.5 mg per 2.5 mL Solution for InhalationLDPE plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 5 ampoules)
Rx
Legency Remedies Pvt. Ltd.India
Boon Pharma Corp.Importer: Suhitas Pharmaceuticals Inc.
DRP-13475-08
Feb 27, 2028
Salbucura PlusIpratropium bromide + Salbutamol (as sulfate)
500 mcg/2.5 mg Solution for InhalationLDPE plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 5 ampoules) (Box of 25’s)
Rx
Legency Remedies Pvt. Ltd.India
Rvm Pharma & Medical Supplies DistributionImporter: Suhitas Pharmaceuticals, Inc.
DRP-13475-10
Feb 27, 2028
Salbunov PlusSalbutamol (as sulfate) + Ipratropium (as bromide)
2.5 mg/500 mcg per 2.5 mL Solution for Inhalation5 ml LDPE Vial in Aluminum Foil Pouch x 7's (Box of 7's)
Rx
Ahlcon Parenterals (India) LimitedIndia
Medinova Pharmaceutical Inc.
DRP-11882
May 16, 2027
Salburex PlusSalbutamol (as Sulfate) + Ipratropium Bromide
2.5 mg/ 500 mcg per 2.5 mL Solution for Nebulization2.5 mL LDPE Form-Fill Seal Ampoule in aluminum pouch (Box of 25’s)
Rx
Legency Remedies Pvt. Ltd.India
Rexmed Pharmaceutical SalesImporter: Hillcross Prime Inc.
DRP-11062-04
Jan 21, 2027
SALMATE IpraSalbutamol (as sulfate) + Ipratropium bromide
2.5 mg/500 mcg Solution for Inhalation5 LDPE Respules x 2.5 mL Packed in Aluminum Foil Pouch (Box of 20's)
Rx
Axa Parenterals LimitedIndia
Preventia Healthcare Inc.
DRP-12113
Jan 7, 2032
Salresp-ISalbutamol (as sulfate) + Ipratropium (as bromide)
2.5 mg/500 mcg per 2.5 mL Solution for InhalationLDPE Nebule x 2.5 mL (Box of 35's and Box of 30's); LDPE Nebule x 2.5 mL (Box of 35's )(with aluminum pouch)
Rx
Ahlcon Parenterals (India) LimitedIndia
I.E. Medica, Inc.
DRP-1419
May 19, 2032
SaltropiumSalbutamol (as sulfate) + Ipratropium bromide
2.5 mg/500 mcg per 2.5 mL Solution for Inhalation2.5 mL (net content) in 5 mL LDPE vial in Aluminum Foil Strip x 7’s (Box of 35’s)
Rx
Ahlcon Parenterals (India) LimitedIndia
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambicare Pharmaceuticals Inc.Trader: Highkon Pharma
DRP-13048-02
Nov 24, 2027
SapiumIpratropium bromide + salbutamol (as sulfate)
500 mcg/2.5 mg per 2.5 mL Solution For InhalationLDPE plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 5 ampoules)
Rx
Legency Remedies Pvt. Ltd.India
Suhitas Pharmaceuticals Inc.
DRP-13475
Feb 27, 2028
Sethair DuoIpratropium bromide + Salbutamol (as sulfate)
500 mcg/2.5 mg Solution for InhalationLDPE plastic ampoule x 2.5 mL (Box of 5 ampoule strips x 5 ampoules)
Rx
Legency Remedies Pvt. Ltd.India
999 Seth Pharmaceutical Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-13475-07
Feb 27, 2028
UnbrandedSalbutamol (as sulfate) + Ipratropium (as bromide)
2.5 mg/500 mcg per 2.5 mL Solution for InhalationLDPE Nebule x 2.5 mL (Box of 35's)
Rx
Ahlcon Parenterals (India) LimitedIndia
Uniqure Pharma Inc.Importer: I.E. Medica, Inc.
DRP-1419-03
May 19, 2027
UnbrandedIpratropium bromide (as monohydrate) + Salbutamol (as sulfate)
500 mcg / 2.5 mg per 2.5 mL Solution for Nebulization2.5 mL LDPE blow-fill-seal ampoule x 5's in an aluminum/PE/PET laminated pouch (Box of 20's)
Rx
Amherst Parenterals, Inc.Laguna
RiteMED Phils., Inc.Trader: UNILAB, Inc.
DRP-16154-01
Dec 22, 2031
UnbrandedIpratropium Bromide + Salbutamol (as Sulfate)
500 mcg/2.5 mg/2.5 mL Solution for InhalationLDPE Vial x 2.5 mL (Box of 20's)
Rx
Laboratoire UnitherFrance
Philusa CorporationImporter: Boehringer Ingelheim (Philippines), Inc.
DRP-7891-01
May 9, 2031
VentulantSalbutamol Sulphate + Ipratropium Bromide
2.5 mg/500 mcg per 2.5 mL Solution for Inhalation2.5 mL Low Density (LDPE) Ampoule x 5's in Aluminum pouch (Box of 30's)
Rx
Legency Remedies Pvt. Ltd.India
PhilRx Pharma, Inc.
DRP - 15355
Jun 28, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS COMBIVENT RESPIMAT consists of a COMBIVENT RESPIMAT inhaler and an aluminum cylinder (COMBIVENT RESPIMAT cartridge) containing a combination of ipratropium bromide (monohydrate) and albuterol sulfate. The COMBIVENT RESPIMAT cartridge is only intended for use with the COMBIVENT RESPIMAT inhaler.

Each actuation from the COMBIVENT RESPIMAT inhaler delivers 20 mcg ipratropium bromide (monohydrate) and 100 mcg albuterol (equivalent to 120 mcg albuterol sulfate) from the mouthpiece. Inhalation spray: 20 mcg ipratropium bromide (monohydrate) and 100 mcg albuterol (equivalent to 120 mcg albuterol sulfate) per actuation with the COMBIVENT RESPIMAT inhaler (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Paradoxical bronchospasm: Discontinue COMBIVENT RESPIMAT immediately and treat with alternative therapy if paradoxical bronchospasm occurs (5.1)
  • Patients with cardiovascular system disorders: Use with caution because of beta-adrenergic stimulation (5.2)
  • Ocular effects: Advise patients to avoid spraying into eyes and to contact a physician if blurred vision, halos, or other visual disturbances occur. Monitor patients with narrow-angle glaucoma. (5.3)
  • Urinary retention: Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction (5.4)
  • Hypersensitivity reactions including anaphylaxis: Discontinue COMBIVENT RESPIMAT and institute alternative therapy if immediate hypersensitivity reactions such as urticaria, angioedema, rash, bronchospasm, anaphylaxis, or oropharyngeal edema occur (5.6)
  • Coexisting conditions: Use with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus (5.7)
5.1 Paradoxical Bronchospasm

5.1 Paradoxical Bronchospasm COMBIVENT RESPIMAT can produce paradoxical bronchospasm that can be life-threatening. If it occurs, therapy with COMBIVENT RESPIMAT should be discontinued immediately and alternative therapy instituted.

5.2 Cardiovascular Effects

5.2 Cardiovascular Effects The albuterol sulfate contained in COMBIVENT RESPIMAT, like other beta‑adrenergic agonists, can produce a clinically significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, and/or symptoms. If these symptoms occur, COMBIVENT RESPIMAT may need to be discontinued.

There is some evidence from postmarketing data and published literature of rare occurrences of myocardial ischemia associated with albuterol. In addition, beta‑adrenergic agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression.

Therefore, COMBIVENT RESPIMAT should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension [see Drug Interactions (7.2)].

5.3 Ocular Effects

5.3 Ocular Effects Ipratropium bromide, a component of COMBIVENT RESPIMAT, is an anticholinergic and may increase intraocular pressure. This may result in precipitation or worsening of narrow-angle glaucoma. Therefore, COMBIVENT RESPIMAT should be used with caution in patients with narrow-angle glaucoma [see Drug Interactions (7.1)].

Patients should avoid spraying COMBIVENT RESPIMAT into the eyes. If a patient sprays COMBIVENT RESPIMAT into their eyes they may cause acute eye pain or discomfort, temporary blurring of vision, mydriasis, visual halos, or colored images in association with red eyes from conjunctival or corneal congestion. Advise patients to consult their physician immediately if any of these symptoms develop while using COMBIVENT RESPIMAT.

5.4 Urinary Retention

5.4 Urinary Retention Ipratropium bromide, a component of COMBIVENT RESPIMAT, is an anticholinergic and may cause urinary retention. Therefore, caution is advised when administering this medication to patients with prostatic hyperplasia or bladder-neck obstruction [see Drug Interactions (7.1)].

5.5 Do Not Exceed Recommended Dosage

5.5 Do Not Exceed Recommended Dosage Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. The exact cause of death is unknown, but cardiac arrest following an unexpected development of a severe acute asthmatic crisis and subsequent hypoxia is suspected [see Drug Interactions (7.2)].

5.6 Hypersensitivity Reactions Including Anaphylaxis

5.6 Hypersensitivity Reactions Including Anaphylaxis Hypersensitivity reactions including urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema may occur after administration of ipratropium bromide or albuterol sulfate. In clinical trials and postmarketing experience with ipratropium containing products, hypersensitivity reactions such as skin rash, pruritus, angioedema of tongue, lips and face, urticaria (including giant urticaria), laryngospasm, and anaphylactic reactions have been reported [see Adverse Reactions (6.1, 6.2)].

If such a reaction occurs, therapy with COMBIVENT RESPIMAT should be stopped at once and alternative treatment should be considered [see Contraindications (4)].

5.7 Coexisting Conditions

5.7 Coexisting Conditions COMBIVENT RESPIMAT contains albuterol sulfate, a beta 2 -adrenergic sympathomimetic amine and, therefore, should be used with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus, and in patients who are unusually responsive to sympathomimetic amines.

5.8 Hypokalemia Beta 2

5.8 Hypokalemia Beta 2 ‑adrenergic agonists may produce significant hypokalemia in some patients (possibly through intracellular shunting) which has the potential to produce adverse cardiovascular effects. The decrease in serum potassium is usually transient, not requiring supplementation [see Drug Interactions (7.2)].

Drug interactions

Drug interactions (US label) US FDA label
  • COMBIVENT RESPIMAT has been used concomitantly with other drugs, including beta-adrenergic bronchodilators, methylxanthines, and oral and inhaled steroids, commonly used in the treatment of chronic obstructive pulmonary disease. There are no formal studies fully evaluating the interaction effects of COMBIVENT RESPIMAT and these drugs with respect to safety and effectiveness. Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7.1)
  • Beta-adrenergic agonists: May increase the risk of adverse cardiovascular effects. Avoid coadministration of COMBIVENT RESPIMAT and other sympathomimetic agents (7.2)
  • Beta-blockers: Inhibit the effect of albuterol. Consider alternative therapy in patients with hyperreactive airways (7.3)
  • Diuretics: Electrocardiographic changes and/or hypokalemia associated with diuretics may worsen with concomitant use of beta-agonists. Consider monitoring potassium levels. (7.4)
  • Monoamine oxidase inhibitors (MAOs) or tricyclic antidepressants: May potentiate effect of albuterol on the vascular system. Consider alternative therapy in patients taking MAOs or tricyclic antidepressants. (7.5)
7.1 Anticholinergic Agents

7.1 Anticholinergic Agents There is the potential for an additive interaction with concomitantly used anticholinergic medications. Therefore, avoid coadministration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects [see Warnings and Precautions (5.3, 5.4)].

7.2 Beta

7.2 Beta‑adrenergic Agonists Caution is advised in the coadministration of COMBIVENT RESPIMAT and other sympathomimetic agents due to the increased risk of adverse cardiovascular effects [see Warnings and Precautions (5.2, 5.5)].

7.3 Beta-receptor Blocking Agents

7.3 Beta-receptor Blocking Agents Beta-receptor blocking agents and albuterol inhibit the effect of each other. Beta-receptor blocking agents should be used with caution in patients with hyperreactive airways.

7.4 Diuretics The

7.4 Diuretics The ECG changes and/or hypokalemia which may result from the administration of non‑potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta 2 -agonists, especially when the recommended dosage of the beta 2 -agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonist‑containing drugs, such as COMBIVENT RESPIMAT, with non‑potassium sparing diuretics.

Consider monitoring potassium levels.

7.5 Monoamine Oxidase Inhibitors or Tricyclic Antidepressants

7.5 Monoamine Oxidase Inhibitors or Tricyclic Antidepressants COMBIVENT RESPIMAT should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants or within 2 weeks of discontinuation of such agents because the action of albuterol on the cardiovascular system may be potentiated. Consider alternative therapy in patients taking MAOs or tricyclic antidepressants [see Warnings and Precautions (5.2)].

Adverse reactions

Adverse reactions (US label) US FDA label
  • Use of albuterol, a beta 2 -adrenergic agonist, may be associated with the following: Paradoxical bronchospasm [see Warnings and Precautions (5.1)] Cardiovascular effects [see Warnings and Precautions (5.2)] Hypersensitivity reactions including anaphylaxis [see Contraindications (4) and Warnings and Precautions (5.6)] Hypokalemia [see Warnings and Precautions (5.8)] Albuterol is a component of COMBIVENT RESPIMAT. Use of ipratropium bromide, an anticholinergic, may result in the following: Ocular effects [see Warnings and Precautions (5.3)] Urinary retention [see Warnings and Precautions (5.4)] Ipratropium bromide is a component of COMBIVENT RESPIMAT. Most common (≥2%) adverse reactions for COMBIVENT RESPIMAT (20/100 mcg) are upper respiratory infection, nasopharyngitis, cough, bronchitis, headache, and dyspnea (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at 1-800-542-6257 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience COMBIVENT RESPIMAT 12-Week Clinical Trials The safety data described in Table 1 below are derived from one 12-week, randomized, multicenter, double-blind, double-dummy, parallel-group trial that compared COMBIVENT RESPIMAT (20/100 mcg), CFC-propelled COMBIVENT Inhalation Aerosol (36/206 mcg), and ipratropium bromide delivered by the RESPIMAT inhaler (20 mcg) administered four times a day in 1,460 adult COPD patients (955 males and 505 females) 40 years of age and older. Of these patients, 486 were treated with COMBIVENT RESPIMAT.

The COMBIVENT RESPIMAT group was composed of mostly Caucasian (88.5%) patients with a mean age of 63.8 years, and a mean percent predicted FEV 1 at screening of 41.5%. Patients with narrow-angle glaucoma, symptomatic prostatic hypertrophy or bladder-neck obstruction were excluded from the trial. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Table 1 shows all adverse reactions that occurred with a frequency of ≥2% in the COMBIVENT RESPIMAT treatment group in the 12-week COPD trial. The frequency of the corresponding adverse reactions in the CFC-propelled COMBIVENT Inhalation Aerosol and ipratropium bromide delivered by the RESPIMAT inhaler groups is included for comparison.

The rates are derived from all reported adverse reactions of that type not present at baseline, whether considered drug-related or not by the clinical investigator. Table 1 Adverse Reactions in ≥2% of Patients in the COMBIVENT RESPIMAT Group in a 12-Week COPD Clinical Trial Body System (Event) 12-Week Ipratropium-Controlled Trial COMBIVENT RESPIMAT (20/100 mcg) CFC-propelled COMBIVENT Inhalation Aerosol (36/206 mcg) Ipratropium bromide by the RESPIMAT Inhaler (20 mcg) [n=486] [n=491] [n=483] Patients with any adverse reaction 46 52 45 Respiratory, thoracic, and mediastinal disorders Cough Dyspnea 3 2 2 2 2 3 Nervous system disorders Headache 3 2 3 Infections and infestations Bronchitis Nasopharyngitis Upper Respiratory infection 3 4 3 3 3 4 1 4 3 Adverse reactions that occurred in <2% in the COMBIVENT RESPIMAT (20/100 mcg) group observed in this 12-week trial include: Vascular disorders: hypertension; Nervous system disorders: dizziness and tremor; Musculoskeletal and connective tissue disorder: muscle spasms and myalgia; Gastrointestinal disorders: diarrhea, nausea, dry mouth, constipation, and vomiting; General disorders and administration site conditions: asthenia, influenza-like illness, and chest discomfort; Eye disorders: eye pain; Metabolism and nutritional disorders: hypokalemia; Cardiac disorders: palpitations and tachycardia; Skin and subcutaneous tissue disorders: pruritus and rash; Respiratory, thoracic, and mediastinal disorders; pharyngolaryngeal pain and wheezing.

A separate 12-week trial evaluated a higher than approved dosage of COMBIVENT RESPIMAT in 1,118 COPD patients. Patients were randomized to COMBIVENT RESPIMAT (40/200 mcg) (n=345), CFC-propelled COMBIVENT Inhalation Aerosol (36/206 mcg) (n=180), ipratropium delivered by the RESPIMAT (40 mcg) (n=252) or placebo (n=341). The overall incidence and nature of adverse reactions observed were similar to the adverse reactions seen with COMBIVENT RESPIMAT 20/100 mcg.

COMBIVENT RESPIMAT Long-Term (48-week) Safety Trial Long-term chronic use safety data for COMBIVENT RESPIMAT were obtained from one 48-week, randomized, multicenter, open-label, parallel-group trial that compared COMBIVENT RESPIMAT (20/100 mcg), CFC-propelled COMBIVENT Inhalation Aerosol (36/206 mcg), and the free combination of ipratropium bromide (34 mcg) and albuterol (180 mcg) HFA inhalation aerosols administered 4 times a day in 465 adult COPD patients (273 males and 192 females) 40 years of age and older. Of these patients, 157 were treated with COMBIVENT RESPIMAT.

The COMBIVENT RESPIMAT group was composed of mostly Caucasian (93.5%) patients with a mean age of 62.9 years, and a mean percent predicted FEV 1 at screening of 47.0%. An evaluation of the safety data from the trial revealed that most adverse reactions were similar in type and rate between treatment groups. However, cough occurred more frequently in patients enrolled in the COMBIVENT RESPIMAT group (7.0%) compared to those in the CFC-propelled COMBIVENT Inhalation Aerosol (2.6%) or the free combination of ipratropium bromide and albuterol HFA inhalation aerosols (3.9%) groups.

In addition to the adverse reactions reported in the controlled clinical trial with COMBIVENT RESPIMAT, adverse reaction information concerning CFC-propelled COMBIVENT Inhalation Aerosol is derived from two 12-week controlled clinical trials (N=358 for CFC-propelled COMBIVENT Inhalation Aerosol). Adverse reactions reported in ≥2% of patients in the CFC-propelled COMBIVENT Inhalation Aerosol treatment group include: bronchitis, upper respiratory tract infection, headache, dyspnea, cough, pain, respiratory disorder, sinusitis, pharyngitis, and nausea.

Adverse reactions reported in <2% of patients in the CFC-propelled COMBIVENT Inhalation Aerosol treatment group include: edema, fatigue, hypertension, dizziness, nervousness, tremor, dysphonia, insomnia, diarrhea, dry mouth, dyspepsia, vomiting, arrhythmia, palpitation, tachycardia, arthralgia, angina, increased sputum, taste perversion, urinary tract infection, dysuria, dry throat, and bronchospasm.

6.2 Postmarketing Experience

6.2 Postmarketing Experience In addition to the adverse reactions reported during clinical trials, the following adverse reactions have been identified during post-approval use of CFC-propelled COMBIVENT Inhalation Aerosol. Since CFC-propelled COMBIVENT Inhalation Aerosol and COMBIVENT RESPIMAT contain the same active ingredients, one should take into account the fact that the adverse reactions seen with CFC-propelled COMBIVENT Inhalation Aerosol could also occur with COMBIVENT RESPIMAT.

Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Eye disorders: glaucoma, blurred vision, mydriasis, conjunctival hyperemia, halo vision, accommodation disorder, ocular irritation, and corneal edema Gastrointestinal disorders: gastrointestinal motility disorder, drying of secretions, stomatitis, and mouth edema Immune system disorders: hypersensitivity Investigations: intraocular pressure increased, blood pressure diastolic decreased, and blood pressure systolic increased Musculoskeletal and connective tissue disorders: muscular weakness Psychiatric disorders: CNS stimulation, mental disorder Respiratory, thoracic, and mediastinal disorders: throat irritation, paradoxical bronchospasm, wheezing, nasal congestion, and pharyngeal edema Skin and subcutaneous tissue disorders: angioedema, hyperhidrosis, and skin reaction Urinary disorders: urinary retention Cardiac disorders: myocardial ischemia Allergic-type reactions such as skin reactions including rash, pruritus, and urticaria (including giant urticaria), angioedema including that of tongue, lips and face, laryngospasm, and anaphylactic reaction have also been reported with CFC-propelled COMBIVENT Inhalation Aerosol, with positive re-challenge in some cases [see Warnings and Precautions (5.6)].

In a 5-year placebo-controlled trial, hospitalizations for supraventricular tachycardia and/or atrial fibrillation occurred with an incidence rate of 0.5% in COPD patients receiving CFC-propelled ATROVENT® (ipratropium bromide) Inhalation Aerosol. Metabolic acidosis has been reported with use of albuterol-containing products.

Adverse reaction frequency tables (US label) US FDA label
Table 1 Adverse Reactions in ≥2% of Patients in the COMBIVENT RESPIMAT Group in a 12-Week COPD Clinical Trial
Body System (Event)12-Week Ipratropium-Controlled Trial
COMBIVENT RESPIMAT (20/100 mcg) CFC-propelled COMBIVENT Inhalation Aerosol (36/206 mcg)Ipratropium bromide by the RESPIMAT Inhaler (20 mcg)
[n=486][n=491][n=483]
Patients with any adverse reaction465245
Respiratory, thoracic, and mediastinal disorders
Cough Dyspnea 3 22 22 3
Nervous system disorders
Headache3 2 3
Infections and infestations
Bronchitis Nasopharyngitis Upper Respiratory infection3 4 33 3 41 4 3

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary There are no randomized clinical studies of COMBIVENT RESPIMAT, or its individual components, ipratropium bromide and albuterol sulfate, in pregnant women. Ipratropium is negligibly absorbed systemically following oral inhalation; therefore, maternal use is not expected to result in fetal exposure to the drug [see Clinical Pharmacology (12.3)].

Published literature, including cohort studies, case control studies and case series, over several decades have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes with ipratropium bromide. Available data from published epidemiological studies and postmarketing case reports of pregnancy outcomes following inhaled albuterol use do not consistently demonstrate a risk of major birth defects or, miscarriage.

There are clinical considerations with the use of COMBIVENT RESPIMAT in pregnant women [see Clinical Considerations]. Animal reproduction studies have not been conducted with COMBIVENT RESPIMAT, however, animal studies are available with its individual components, ipratropium bromide and albuterol sulfate. Based on oral reproduction studies, no evidence of structural alterations was observed when ipratropium bromide was administered to pregnant mice, rats, and rabbits during organogenesis at doses approximately 340, 68,000 and 17,000 times, respectively, the maximum recommended human daily inhalation dose (MRHDID) in adults on a mg/m 2 basis.

When albuterol was administered to pregnant mice during organogenesis there was evidence of cleft palate at doses approximately equivalent to the maximum recommended human daily inhalation dose (MRHDID) [see Data]. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Consideration Labor or Delivery Because of the potential for beta-agonist interference with uterine contractility, use of COMBIVENT RESPIMAT for the treatment of COPD during labor should be restricted to those patients in whom the benefits clearly outweigh the risk.

Serious adverse reactions, including pulmonary edema, have been reported during or following treatment of premature labor with beta 2 -agonists, including albuterol. Data Animal Data Ipratropium bromide In animal reproduction studies, oral and inhalation administration of ipratropium bromide to pregnant mice, rats and rabbits during the period of organogenesis did not show evidence of fetal structural alterations.

The ipratropium dose in oral studies in mice, rats, and rabbits was up to approximately 340, 68,000 and 17,000 times, respectively, the maximum recommended human daily inhalation dose (MRHDID) in adults (on a mg/m 2 basis at maternal doses in each species of 10, 1,000 and 125 mg/kg/day, respectively). The ipratropium dose in inhalation studies in rats and rabbits was up to approximately 100 and 240 times, respectively, the MRHDID in adults (on a mg/m 2 basis at maternal doses of 1.5 and 1.8 mg/kg/day, respectively).

Embryotoxicity was observed as increased resorption in rats at oral doses approximately 6,100 times MRHDID in adults (on a mg/m 2 basis at maternal doses of 90 mg/kg/day and above). This effect is not considered relevant to human use due to the large doses at which it was observed and the difference in route of administration.

Albuterol In a mouse reproduction study, subcutaneously administered albuterol sulfate produced cleft palate formation in 5 of 111 (4.5%) fetuses at a dose approximately equivalent to the MRHDID in adults (on a mg/m 2 basis at a maternal dose of 0.25 mg/kg/day) and in 10 of 108 (9.3%) fetuses at approximately 14 times the MRHDID in adults (on a mg/m 2 basis at a maternal dose of 2.5 mg/kg/day). Similar effects were not observed at approximately less than MRHDID in adults (on a mg/m 2 basis at a maternal dose of 0.025 mg/kg/day).

Cleft palate also occurred in 22 of 72 (30.5%) fetuses from females treated with 2.5 mg/kg/day isoproterenol (positive control). In a rabbit reproductive study, orally administered albuterol sulfate induced cranioschisis in 7 of 19 (37%) fetuses at approximately 1,100 times the MRHDID in adults (on a mg/m 2 basis at a maternal dose of 50 mg/kg/day).

In a rat reproduction study, an albuterol sulfate/HFA-134a formulation administered by inhalation did not produce any teratogenic effects at exposures approximately 80 times the MRHDID (on a mg/m 2 basis at a maternal dose of 10.5 mg/kg). A study in which pregnant rats were dosed with radiolabeled albuterol sulfate demonstrated that drug-related material is transferred from the maternal circulation to the fetus.

Mechanism of action

12.1 Mechanism of Action COMBIVENT RESPIMAT: COMBIVENT RESPIMAT is a combination of the anticholinergic ipratropium bromide and the beta 2 -adrenergic agonist albuterol sulfate. The mechanisms of action described below for the individual components apply to COMBIVENT RESPIMAT. The two classes of medications (an anticholinergic and a beta 2 -adrenergic agonist) are both bronchodilators.

Simultaneous administration of both an anticholinergic (ipratropium bromide) and a beta 2 -sympathomimetic (albuterol sulfate) is designed to produce a greater bronchodilator effect than when either drug is utilized alone at its recommended dosage. The efficacy of COMBIVENT RESPIMAT is likely to be due to a local effect on the muscarinic and beta 2 -adrenergic receptors in the lung.

Ipratropium bromide Ipratropium bromide is an anticholinergic (parasympatholytic) agent which, based on animal studies, appears to inhibit vagally mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released at the neuromuscular junctions in the lung. Anticholinergics prevent the increases in intracellular concentration of Ca++ which is caused by interaction of acetylcholine with the muscarinic receptors on bronchial smooth muscle.

Albuterol sulfate In vitro studies and in vivo pharmacology studies have demonstrated that albuterol has a preferential effect on beta 2 -adrenergic receptors compared with isoproterenol. While it is recognized that beta 2 -adrenergic receptors are the predominant receptors on bronchial smooth muscle, recent data indicate that there is a population of beta 2 -receptors in the human heart which comprise between 10% and 50% of cardiac beta-adrenergic receptors.

The precise function of these receptors, however, is not yet established [see Warnings and Precautions (5.2)]. Activation of beta 2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylyl cyclase and to an increase in the intracellular concentration of cyclic-3',5'-adenosine monophosphate (cyclic AMP).

This increase of cyclic AMP leads to the activation of protein kinase, which inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in relaxation. Albuterol relaxes the smooth muscles of all airways, from the trachea to the terminal bronchioles. Albuterol acts as a functional antagonist to relax the airway irrespective of the spasmogen involved, thus protecting against all bronchoconstrictor challenges.

Increased cyclic AMP concentrations are also associated with the inhibition of release of mediators from mast cells in the airway. Albuterol has been shown in most clinical trials to have more bronchial smooth muscle relaxation effect than isoproterenol at comparable doses while producing fewer cardiovascular effects. However, all beta‑adrenergic agonist drugs, including albuterol sulfate, can produce a significant cardiovascular effect in some patients [see Warnings and Precautions (5.2)].

Ipratropium bromide Ipratropium bromide is an anticholinergic (parasympatholytic) agent which, based on animal studies, appears to inhibit vagally mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released at the neuromuscular junctions in the lung. Anticholinergics prevent the increases in intracellular concentration of Ca++ which is caused by interaction of acetylcholine with the muscarinic receptors on bronchial smooth muscle.

Albuterol sulfate In vitro studies and in vivo pharmacology studies have demonstrated that albuterol has a preferential effect on beta 2 -adrenergic receptors compared with isoproterenol. While it is recognized that beta 2 -adrenergic receptors are the predominant receptors on bronchial smooth muscle, recent data indicate that there is a population of beta 2 -receptors in the human heart which comprise between 10% and 50% of cardiac beta-adrenergic receptors.

The precise function of these receptors, however, is not yet established [see Warnings and Precautions (5.2)]. Activation of beta 2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylyl cyclase and to an increase in the intracellular concentration of cyclic-3',5'-adenosine monophosphate (cyclic AMP).

This increase of cyclic AMP leads to the activation of protein kinase, which inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in relaxation. Albuterol relaxes the smooth muscles of all airways, from the trachea to the terminal bronchioles. Albuterol acts as a functional antagonist to relax the airway irrespective of the spasmogen involved, thus protecting against all bronchoconstrictor challenges.

Increased cyclic AMP concentrations are also associated with the inhibition of release of mediators from mast cells in the airway. Albuterol has been shown in most clinical trials to have more bronchial smooth muscle relaxation effect than isoproterenol at comparable doses while producing fewer cardiovascular effects. However, all beta‑adrenergic agonist drugs, including albuterol sulfate, can produce a significant cardiovascular effect in some patients [see Warnings and Precautions (5.2)].

Ipratropium bromide Cardiovascular effects At recommended dosages, ipratropium bromide does not produce clinically significant changes in pulse rate or blood pressure. Ocular effects In studies without a positive control, ipratropium bromide did not alter pupil size, accommodation, or visual acuity. Mucociliary clearance and respiratory secretions Controlled clinical studies have demonstrated that ipratropium bromide does not alter either mucociliary clearance or the volume or viscosity of respiratory secretions.

Albuterol sulfate Cardiovascular effects Controlled clinical trials and other clinical experience have shown that inhaled albuterol, like other beta-adrenergic agonist drugs, can produce a significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, symptoms, and/or electrocardiographic changes.

Ipratropium bromide Ipratropium bromide is a quaternary amine and hence, it is not readily absorbed into the systemic circulation either from the surface of the lung or from the gastrointestinal tract as confirmed by blood level and renal excretion studies. The half-life of elimination is about 2 hours after inhalation or intravenous administration.

Ipratropium bromide is minimally bound (0% to 9% in vitro) to plasma albumin and α 1 -acid glycoprotein. It is partially metabolized to inactive ester hydrolysis products. Following intravenous administration, approximately one-half of the dose is excreted unchanged in the urine.

Albuterol sulfate Albuterol is longer acting than isoproterenol in most patients because it is not a substrate for the cellular uptake processes for catecholamines, nor for metabolism by catechol-O-methyl transferase. Instead, the drug is conjugatively metabolized to albuterol 4'-O-sulfate. Intravenous pharmacokinetics of albuterol was studied in a comparable group of 16 healthy male volunteers; the mean terminal half-life following a 30-minute infusion of 1.5 mg was 3.9 hours, with a mean clearance of 439 mL/min/1.73 m².

COMBIVENT RESPIMAT Inhalation Spray In a 12-week randomized, multicenter, double-blind, double-dummy parallel group trial, 108 US patients with COPD receiving either COMBIVENT RESPIMAT (20/100 mcg) or CFC-propelled COMBIVENT Inhalation Aerosol (36/206 mcg) four times daily participated in pharmacokinetic evaluations. Plasma ipratropium concentrations were low with an average peak plasma concentration of 33.5 pg/mL from COMBIVENT RESPIMAT.

The majority of the study participants exhibited levels below the lower limit of quantitation (<10 pg/mL) by 4 to 6 hours following dosing. The steady state systemic exposure obtained for ipratropium bromide following COMBIVENT RESPIMAT was comparable to that of CFC-propelled COMBIVENT Inhalation Aerosol. Ipratropium plasma AUC and total amount of drug excreted unchanged in urine (Ae) ratios for COMBIVENT RESPIMAT/CFC-propelled COMBIVENT Inhalation Aerosol were 1.04 and 1.18, respectively.

For albuterol the steady state systemic exposure was less from COMBIVENT RESPIMAT compared to that of CFC-propelled COMBIVENT Inhalation Aerosol. Albuterol plasma AUC and urine Ae ratios for COMBIVENT RESPIMAT/CFC-propelled COMBIVENT Inhalation Aerosol were 0.74 and 0.86, respectively. Pharmacokinetic drug-drug interaction between ipratropium bromide and albuterol sulfate was evaluated in a crossover study in 12 healthy male volunteers who received CFC-propelled COMBIVENT Inhalation Aerosol and the two active components separately as individual treatments.

Results from this study indicated that the coadministration of these two components from a single canister did not significantly alter the systemic absorption of either component, indicating lack of any pharmacokinetic interaction between these two drugs.

Specific Populations Age Consistent with CFC-propelled COMBIVENT Inhalation Aerosol (36/206 mcg), patients receiving COMBIVENT RESPIMAT (20/100 mcg) aged 65 years and over had higher steady state systemic exposures than patients aged under 65 years for both ipratropium (AUC = 166 vs. 105 pg•hr/mL, C max = 38.5 vs. 30.1 pg/mL) and albuterol (AUC = 5.44 vs. 3.27 ng•hr/mL, C max = 1.19 vs. 0.74 ng/mL). Gender The AUC and C max values for ipratropium were 131 pg.hr/mL and 35.4 pg/mL in males and 123 pg.hr/mL and 31.7 pg/mL in females, respectively.

The AUC- and C max -values for albuterol were 4.0 ng•hr/mL and 0.89 ng/mL in males and 4.2 ng•hr/mL and 0.93 ng/mL in females, respectively. Hepatic and Renal Impairment The pharmacokinetics of COMBIVENT RESPIMAT or ipratropium bromide has not been studied in patients with hepatic or renal insufficiency. Drug-Drug Interactions No specific pharmacokinetic studies were conducted to evaluate potential drug-drug interactions with other medications.

Ipratropium bromide Two-year oral carcinogenicity studies in rats and mice have revealed no carcinogenic activity at doses up to 6 mg/kg/day (approximately 400 and 200 times the maximum recommended human daily inhalation dose of ipratropium bromide (MRHDID) in adults on a mg/m 2 basis, respectively). Results of various mutagenicity/clastogenicity studies (Ames test, mouse dominant lethal test, mouse micronucleus test, and chromosome aberration of bone marrow in Chinese hamsters) were negative.

Fertility of male or female rats at oral doses up to 50 mg/kg/day (approximately 3,400 times the MRHDID in adults on a mg/m 2 basis) was unaffected by ipratropium bromide administration. At an oral dose of 500 mg/kg/day (approximately 34,000 times the MRHDID in adults on a mg/m 2 basis), ipratropium bromide produced a decrease in the conception rate.

Albuterol Like other agents in its class, albuterol caused a significant dose-related increase in the incidence of benign leiomyomas of the mesovarium in a 2-year study in the rat at dietary doses of 2, 10, and 50 mg/kg/day (approximately 20, 110, and 560 times the MRHDID on a mg/m 2 basis). In another study this effect was blocked by the coadministration of propranolol.

The relevance of these findings to humans is not known. An 18-month study in mice at dietary doses up to 500 mg/kg/day (approximately 2,800 times the MRHDID on a mg/m 2 basis) and a 99-week study in hamsters at oral doses up to 50 mg/kg/day (approximately 470 times the MRHDID on a mg/m 2 basis) revealed no evidence of tumorigenicity.

Studies with albuterol revealed no evidence of mutagenesis. Reproduction studies in rats with albuterol sulfate revealed no evidence of impaired fertility.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Ipratropium bromide Cardiovascular effects At recommended dosages, ipratropium bromide does not produce clinically significant changes in pulse rate or blood pressure. Ocular effects In studies without a positive control, ipratropium bromide did not alter pupil size, accommodation, or visual acuity.

Mucociliary clearance and respiratory secretions Controlled clinical studies have demonstrated that ipratropium bromide does not alter either mucociliary clearance or the volume or viscosity of respiratory secretions. Albuterol sulfate Cardiovascular effects Controlled clinical trials and other clinical experience have shown that inhaled albuterol, like other beta-adrenergic agonist drugs, can produce a significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, symptoms, and/or electrocardiographic changes.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

12.3 Pharmacokinetics Ipratropium bromide Ipratropium bromide is a quaternary amine and hence, it is not readily absorbed into the systemic circulation either from the surface of the lung or from the gastrointestinal tract as confirmed by blood level and renal excretion studies.

The half-life of elimination is about 2 hours after inhalation or intravenous administration.

Following intravenous administration, approximately one-half of the dose is excreted unchanged in the urine.

Intravenous pharmacokinetics of albuterol was studied in a comparable group of 16 healthy male volunteers; the mean terminal half-life following a 30-minute infusion of 1.5 mg was 3.9 hours, with a mean clearance of 439 mL/min/1.73 m 2 .

Ipratropium plasma AUC and total amount of drug excreted unchanged in urine (Ae) ratios for COMBIVENT RESPIMAT/CFC-propelled COMBIVENT Inhalation Aerosol were 1.04 and 1.18, respectively.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Ipratropium bromide Ipratropium bromide is a quaternary amine and hence, it is not readily absorbed into the systemic circulation either from the surface of the lung or from the gastrointestinal tract as confirmed by blood level and renal excretion studies. The half-life of elimination is about 2 hours after inhalation or intravenous administration.

Ipratropium bromide is minimally bound (0% to 9% in vitro) to plasma albumin and α 1 -acid glycoprotein. It is partially metabolized to inactive ester hydrolysis products. Following intravenous administration, approximately one-half of the dose is excreted unchanged in the urine. Albuterol sulfate Albuterol is longer acting than isoproterenol in most patients because it is not a substrate for the cellular uptake processes for catecholamines, nor for metabolism by catechol-O-methyl transferase.

Instead, the drug is conjugatively metabolized to albuterol 4'-O-sulfate. Intravenous pharmacokinetics of albuterol was studied in a comparable group of 16 healthy male volunteers; the mean terminal half-life following a 30-minute infusion of 1.5 mg was 3.9 hours, with a mean clearance of 439 mL/min/1.73 m². COMBIVENT RESPIMAT Inhalation Spray In a 12-week randomized, multicenter, double-blind, double-dummy parallel group trial, 108 US patients with COPD receiving either COMBIVENT RESPIMAT (20/100 mcg) or CFC-propelled COMBIVENT Inhalation Aerosol (36/206 mcg) four times daily participated in pharmacokinetic evaluations.

Plasma ipratropium concentrations were low with an average peak plasma concentration of 33.5 pg/mL from COMBIVENT RESPIMAT. The majority of the study participants exhibited levels below the lower limit of quantitation (<10 pg/mL) by 4 to 6 hours following dosing. The steady state systemic exposure obtained for ipratropium bromide following COMBIVENT RESPIMAT was comparable to that of CFC-propelled COMBIVENT Inhalation Aerosol.

Ipratropium plasma AUC and total amount of drug excreted unchanged in urine (Ae) ratios for COMBIVENT RESPIMAT/CFC-propelled COMBIVENT Inhalation Aerosol were 1.04 and 1.18, respectively. For albuterol the steady state systemic exposure was less from COMBIVENT RESPIMAT compared to that of CFC-propelled COMBIVENT Inhalation Aerosol.

Albuterol plasma AUC and urine Ae ratios for COMBIVENT RESPIMAT/CFC-propelled COMBIVENT Inhalation Aerosol were 0.74 and 0.86, respectively. Pharmacokinetic drug-drug interaction between ipratropium bromide and albuterol sulfate was evaluated in a crossover study in 12 healthy male volunteers who received CFC-propelled COMBIVENT Inhalation Aerosol and the two active components separately as individual treatments.

Results from this study indicated that the coadministration of these two components from a single canister did not significantly alter the systemic absorption of either component, indicating lack of any pharmacokinetic interaction between these two drugs. Specific Populations Age Consistent with CFC-propelled COMBIVENT Inhalation Aerosol (36/206 mcg), patients receiving COMBIVENT RESPIMAT (20/100 mcg) aged 65 years and over had higher steady state systemic exposures than patients aged under 65 years for both ipratropium (AUC = 166 vs. 105 pg•hr/mL, C max = 38.5 vs. 30.1 pg/mL) and albuterol (AUC = 5.44 vs. 3.27 ng•hr/mL, C max = 1.19 vs. 0.74 ng/mL).

Gender The AUC and C max values for ipratropium were 131 pg.hr/mL and 35.4 pg/mL in males and 123 pg.hr/mL and 31.7 pg/mL in females, respectively. The AUC- and C max -values for albuterol were 4.0 ng•hr/mL and 0.89 ng/mL in males and 4.2 ng•hr/mL and 0.93 ng/mL in females, respectively. Hepatic and Renal Impairment The pharmacokinetics of COMBIVENT RESPIMAT or ipratropium bromide has not been studied in patients with hepatic or renal insufficiency.

Drug-Drug Interactions No specific pharmacokinetic studies were conducted to evaluate potential drug-drug interactions with other medications.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Ipratropium + Salbutamol 500 mcg + 2.5 mg x 2.5 mL (unit dose) Respiratory Solution₱7.00–₱24.41Reference ₱9.65per unitDPRI procurement range
20 mcg (as bromide) + 100 mcg x 200 doses x 10 mL MDI₱1,083.00per unitPhilHealth GAMOT fixed fee
500 mcg (as bromide anhydrous) + 2.5 mg (as base) respiratory solution in 2.5 mL unit dose (for nebulization)₱45.25per unitPhilHealth GAMOT fixed fee

PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Ipratropium + Salbutamol
PNF listingMDI: 20 micrograms ipratropium (as bromide) + 100 micrograms salbutamol x 200 doses x 10mL
PNF listingResp. Soln.: (for nebulization)
PNF listingResp. Soln.: 500 micrograms ipratropium (as bromide anhydrous) + 2.5 mg salbutamol (as base) x
PNF listingResp. Soln.: 2.5 mL (unit dose)
PhilHealth GAMOTYes (listed since July 28, 2025)

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Combivent Respimat · Boehringer Ingelheim Pharmaceuticals, Inc. [US FDA-approved label, version 18, December 1, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9832312e-0310-4ab6-8501-afa976fc7eb2
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  5. PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  6. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .